Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT04574648 |
Other study ID # |
H18-01332_1 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 1, 2021 |
Est. completion date |
July 31, 2024 |
Study information
Verified date |
November 2020 |
Source |
University of British Columbia |
Contact |
Jeffrey P Hau, MSc |
Phone |
6048754111 |
Email |
jeffrey.hau[@]ubc.ca |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Repeat non-adherence to medications is a common cause of preventable adverse drug events.
Health information technologies have the potential to improve information continuity.
However, they rarely interoperate to ensure providers can view non-adherence information
documented in other systems. The investigators designed ActionADE to enable rapid
documentation of adverse drug events, including non-adherence, and communicate the
information across health sectors by integrating ActionADE with legacy systems.
The investigators will leverage ActionADE's implementation to conduct a randomized trial on
patients diagnosed with an adverse events due to non-adherence. This study will take place in
Vancouver, British Columbia, Canada.
Description:
Medication use is rising due to an aging population and expanding treatment indications for
chronic diseases. Simultaneously, adverse drug events-harmful and unintended events related
to medication use or misuse-have increased. In Canada, adverse events to outpatient
medications cause over two million emergency department visits and 700,000 hospital
admissions, costing over $1 billion in healthcare expenditures annually. Optimizing the
benefits of medications while limiting their potential for harm is a public health priority
across patient populations, health settings and medical disciplines.
The second most common subset of adverse events to outpatient medications was caused by
non-adherence. Non-adherence has been associated with increased downstream health services
utilization and costs of care, likely reflective of worse patient outcomes. It is unknown to
what extent communication about non-adherence to outpatient medications can assist the care
team in reinforcing patient adherence.
Patients with adverse events due to non-adherence often seek care in hospitals due to the
unexpected and serious nature of these events. After assessment and treatment, patients are
discharged back into the care of a community-based provider who often cannot access the
hospital's medical record, may not receive a legible or detailed discharge summary.
Therefore, community-based care providers risk managing the patient without knowing about the
patient's non-adherence, and inappropriately up-titrating medication doses, or simply missing
an opportunity to emphasize the importance of adherence.
The investigators developed ActionADE to address this type of information discontinuity.
ActionADE was integrated to a province-wide network that links all pharmacies in British
Columbia to a central data system, allowing users to see their patient's medication
dispensing history.
The investigators will conduct a triple-blind randomized controlled trial to evaluate the
effectiveness of ActionADE on preventing subsequent non-adherence. The trial will take place
in two urban tertiary care (Vancouver General and Saint Paul's Hospitals) and one urban
community hospital (Lions Gate Hospital) within the Greater Vancouver area, in British
Columbia, Canada. Other hospitals may be added to accelerate recruitment into the trial if
approved by the British Columbia Ministry of Health.
The primary objective of the trial is to evaluate the effect of providing information
continuity about non-adherence using ActionADE on adherence over 12 months compared to
standard care. Secondary objectives for both trials are to evaluate the effect on outpatient
and emergency department visits, admissions, hospital-days and mortality.